Search Result

Results for "

Pim+kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (9) Autophagy (4) c-Myc (1) Caspase (1) DYRK (1) Eukaryotic Initiation Factor (eIF) (1) MDM-2/p53 (1) MNK (1) mTOR (2) PARP (1) Pim (32) Reference Standards (3) STAT (1)
By Research Areas:	Cancer (31) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15604

AZD1208 Maximum Cited Publications 22 Publications Verification	Pim Autophagy Apoptosis	Cancer
AZD1208 is an orally bioavailable, highly selective *PIM* kinases inhibitor .

HY-101126

TP-3654 4 Publications Verification	Pim	Cancer
TP-3654 is a second-generation *Pim* kinase inhibitor with K_i values of 5 and 42 nM for Pim-1 and Pim-3, respectively.

HY-13287

SGI-1776 free base 5+ Cited Publications	Pim Autophagy Apoptosis	Cancer
SGI-1776 free base is an inhibitor of *Pim* kinases, with IC₅₀s of 7 nM, 363 nM, and 69 nM for Pim-1, -2 and -3, respectively.

HY-18095

CX-6258 3 Publications Verification	Pim	Cancer
CX-6258 is a potent and kinase selective pan-Pim kinases inhibitor, with IC₅₀s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-19322B

PIM-447 dihydrochloride 5+ Cited Publications LGH447 dihydrochloride	Pim Apoptosis	Cancer
PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM* kinase* inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis .

HY-101947

SMI-16a 5+ Cited Publications PIM1/2 Kinase Inhibitor VI	Pim	Cancer
SMI-16a is a selective *Pim* kinase inhibitor with IC₅₀ values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.

HY-16976

GDC-0339 2 Publications Verification	Pim	Cancer
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with K_is of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma .

HY-19322

PIM447 5+ Cited Publications LGH447	Pim Apoptosis	Cancer
PIM447 (LGH447) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces apoptosis .

HY-12830

M-110	Pim	Cancer
M-110 is a highly selective, ATP-competitive inhibitor of *PIM kinases* with a preference for PIM-3 (IC₅₀=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC₅₀s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC₅₀s of 0.6 to 0.9 μM .

HY-18095A

CX-6258 hydrochloride hydrate 3 Publications Verification	Pim	Cancer
CX-6258 hydrochloride hydrate is a potent and kinase selective pan-Pim kinases inhibitor, with IC₅₀s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-101870B

Uzansertib phosphate INCB053914 phosphate	Pim	Cancer
Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-101870

Uzansertib INCB053914	Pim	Cancer
Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-18095B

CX-6258 hydrochloride 3 Publications Verification	Pim	Cancer
CX-6258 hydrochloride is a potent and kinase selective pan-Pim kinases inhibitor, with IC₅₀s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-W412264

*Pim-1/2 kinase* inhibitor 1**	Pim	Cancer
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of *Pim kinases* to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27 ^Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer .

HY-123141

K00135	Pim	Cancer
K00135 is a potent and selective inhibitor of *PIM kinases*. K00135 inhibits survival and clonogenic growth of acute leukemia cells. K00135 inhibits the phosphorylation of PIM downstream targets .

HY-101783

GNE-955	Pim	Cancer
GNE-955 is a potent and orally active pan *Pim kinase* inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.

HY-164460

AZD1897	Pim	Cancer
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC₅₀ values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways .

HY-142656

PIM-IN-1	Pim	Cancer
PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, EC₅₀ = 61 nM; pS6, EC₅₀ = 71 nM).

HY-13287A

SGI-1776	Pim Apoptosis Autophagy	Inflammation/Immunology Cancer
SGI-1776 is an inhibitor of *Pim kinases, with IC₅₀*s of 7 nM, 363 nM, and 69 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-133850

10-DEBC	Pim	Cancer
10-DEBC is a selective Akt inhibitor. 10-DEBC shows strong inhibitory activity against Moloney murine leukemia virus (Pim) kinase-1 (IC₅₀=1.28 μM) .

HY-15901A

LGB321 monohydrochloride	Pim mTOR	Cancer
LGB321 monohydrochloride is a potent, selective, orally active and ATP competitive inhibitor of all three *PIM* kinases. LGB321 monohydrochloride inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD in a number of cell lines derived from diverse hematologic malignancies. LGB321 monohydrochloride can be used for the research of hematologic malignancies .

HY-115837

DHPCC-9	Pim	Others
DHPCC-9 acts as an inhibitor of Pim kinase.

HY-15604A

AZD1208 hydrochloride	Pim Autophagy Apoptosis	Cancer
AZD1208 hydrochloride is an orally bioavailable, highly selective *PIM* kinases inhibitor .

HY-160006

PIM-IN-2	Pim	Cancer
PIM-IN-2 (Pim-2) is a *Pim* kinases inhibitor (IC₅₀ = 25 nM). PIM-IN-2 promotes cell survival, is antiapoptotic, and has exhibited an elevated level of expression in a variety of human tumors .

HY-183198

PIM-IN-5	Pim	Cancer
PIM-IN-5 is a *PIM* kinase inhibitor. PIM-IN-5 can be used for the research of acute myeloid leukemia .

HY-101126R

TP-3654 (Standard)	Pim Reference Standards	Cancer
TP-3654 (Standard) is the analytical standard of TP-3654 (HY-101126). This product is intended for research and analytical applications. TP-3654 is a second-generation Pim kinase inhibitor with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively.

HY-101947R

SMI-16a (Standard) PIM1/2 Kinase Inhibitor VI (Standard)	Reference Standards Pim	Cancer
SMI-16a (Standard) is the analytical standard of SMI-16a (HY-101947). This product is intended for research and analytical applications. SMI-16a is a selective Pim kinase inhibitor with IC₅₀ values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.

HY-18088

PIM-IN-4	Pim	Cancer
PIM-IN-4 is a *Pim* kinase inhibitor with K_i values of 2, 3, and 0.5 nM against Pim-1, 2, 3, respectively. PIM-IN-4 blocks the phosphorylation of the pro-apoptotic protein Bad. PIM-IN-4 inhibits the growth of leukemia cells. PIM-IN-4 is applicable for leukemia-related research .

HY-101870BR

Uzansertib phosphate (Standard) INCB053914 phosphate (Standard)	Reference Standards Pim	Cancer
Uzansertib phosphate (Standard) is the analytical standard of Uzansertib phosphate (HY-101870B). This product is intended for research and analytical applications. Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-182957

MNK/PIM-IN-2	MNK Pim Apoptosis Caspase Eukaryotic Initiation Factor (eIF) PARP c-Myc	Cancer
MNK/PIM-IN-2 is a *Mnk/Pim* kinase inhibitor with an IC₅₀ of 32 nM for Mnk1, 3 nM for Mnk2, and 37 nM for Pim1. MNK/PIM-IN-2 reduces the levels of p-eIF4E and p-4EBP1. MNK/PIM-IN-2 induces cell cycle arrest, apoptosis (apoptosis) and exerts antiproliferative effects in leukemia cells. MNK/PIM-IN-2 can be used in studies related to leukemia .

HY-122670

VS-II-173	Pim Apoptosis AMPK DYRK STAT MDM-2/p53	Cancer
VS-II-173 is a pan-Pim kinase inhibitor with IC₅₀ values of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPK_α1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC₅₀ > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations .

HY-181925

FD2024	Apoptosis Pim mTOR	Cancer
FD2024 is a pan-PIM* kinase* inhibitor with IC₅₀ values of 0.17 nM, 1.86 nM, and 0.38 nM against PIM-1, PIM-2, and PIM-3, respectively. FD2024 induces cell apoptosis. FD2024 inhibits the phosphorylation of mTOR, p70S6K, S6, 4EBP1, and BAD proteins. FD2024 exhibits anti-acute myeloid leukemia activity. FD2024 can be used in studies related to acute myeloid leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

Pim+kinases

Inhibitors & Agonists